The effect of perphenazine on methamphetamine dependence

The effect of adding perphenazine to Matrix intervention on control of craving and relapse in methamphetamine users

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090801002266N13

Enrollment

Registered

2020-03-17

Start date

2019-11-22

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine use disorder. Mental and behavioral disorders due to use of other stimulants, including caffeine

Interventions

Intervention 1: Intervention group: In the intervention group, buprenorphine will be started in a sublingual form (made by Mehr Pharmaceutical Company) at 2 mg daily and increase to 4 mg / day (2 subl

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Methamphetamine use disorder criteria based on DSM5 Ages 18 to 50 years Dependence only on methamphetamine Non-pregnancy and lactation Lack of psychosis or severe mood disorder requiring hospitalization Non-simultaneous use of other substances Non-simultaneous use of psychiatric medicines

Exclusion criteria

Exclusion criteria: Unwillingness to continue collaborating during the study Psychiatric problems requiring hospitalization during the study

Design outcomes

Primary

Measure	Time frame
Substance use craving. Timepoint: weeks 1-8 and 12,16,20,and 24. Method of measurement: questionair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza kheirabadi

Esfahan University of Medical Sciences

kheirabadi@bsrc.mui.ac.ir0098 21 352223198

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026